Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
9075
¥ millionWording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales97,406¥ millionYear on year +10.3%Progress 101.8%
Operating profit-2,927¥ million
Ordinary income-1,162¥ million
Net income attributable to owners of the parent13,779¥ millionYear on year +15.2%Progress 95.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥331.54
Operating Margin-3
Financial position at period-end
Total assets275,086¥ million
of which net assets 231,536 ¥ millionEquity ratio 83.7%vs. prior year-end -1.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-1,485
Investment+17,500
Financials-10,255
Net change+5,760
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥53,971 million
Segment revenue
Pharmaceuticals77,95080.0%
Information Services14,23714.6%
Construction and Facility Maintenance4,3314.4%
Product Sales8860.9%
Segment profit
Pharmaceuticals-4,524
Information Services1,102
Construction and Facility Maintenance595
Product Sales136
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥95,700 million (YoY -1.8%)
Operating profit¥4,400 million
Ordinary income¥6,000 million
Net income¥14,500 million (YoY +5.2%)
Annual Dividend Forecast¥160 → ¥170（+6.3%）
Payout ratio48.3% for the fiscal year ended March 2026; forecast 47.7% for the fiscal year ending March 2027
Shareholder Return PolicyAim for a dividend payout ratio of at least 40%; implement progressive ordinary dividends; plan total dividends of ¥27 billion over the five-year Beyond 80 period; and plan share repurchases of ¥6 billion per year, or ¥30 billion in total over five years.
Factors Behind Changes in Business Performance
Revenue increased in the Pharmaceuticals business due to growth in sales of major products and in the Information Services business due to orders for projects related to the GIGA School Program. However, higher cost of sales as a percentage of revenue and increased selling, general and administrative expenses, mainly research and development expenses, resulted in an operating loss and an ordinary loss, while gains on sales of investment securities led to an increase in net income.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNewly included: 0 companies; excluded: 0 companies (no material change in the scope of consolidation during the period)
Material subsequent eventsEntered into an agreement licensing the development and marketing rights for olutasidenib in Taiwan to Orient EuroPharma. Also resolved to acquire up to 1,300,000 shares of treasury stock for a total of up to ¥6 billion and cancel all shares acquired.
Impairment lossNo impairment loss recognized for the period (¥0 million)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥833 million, Gain on sale of investment securities ¥17,044 million, Relocation compensation ¥371 million / Extraordinary loss Losses on disposal of fixed assets ¥132 million, Loss on sale of investment securities ¥62 million
Depreciation and amortization¥4,644 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for securities analysts and institutional investors)
Issued Shares at Period-End46,541,985
Treasury Shares at Period-End5,089,961
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥97,406 million (YoY +10.3%) |
| Operating profit | ¥-2,927 million |
| Ordinary income | ¥-1,162 million |
| Profit attributable to owners of the parent | ¥13,779 million (YoY +15.2%) |
| Net income per share | ¥331.54 |
| Operating Margin | -3 |
| Equity ratio | End of the current fiscal period 83.7 / End of previous period 85.6 |
| Total assets | ¥275,086 million |
| Net assets | ¥231,536 million |
| Cash flows from operating activities | ¥-1,485 million |
| Cash flows from investing activities | ¥17,500 million |
| Cash flows from financing activities | ¥-10,255 million |
| Cash and cash equivalents at end of period | ¥53,971 million |
| Full-year earnings forecast | Net Sales ¥95,700 million (YoY -1.8%) / Operating profit ¥4,400 million / Ordinary income ¥6,000 million / Net income ¥14,500 million (YoY +5.2%) |
| Annual Dividend Forecast | ¥160 → ¥170（+6.3%） |
| Payout ratio | 48.3% for the fiscal year ended March 2026; forecast 47.7% for the fiscal year ending March 2027 |
| Shareholder Return Policy | Aim for a dividend payout ratio of at least 40%; implement progressive ordinary dividends; plan total dividends of ¥27 billion over the five-year Beyond 80 period; and plan share repurchases of ¥6 billion per year, or ¥30 billion in total over five years. |
| Segment revenue | Segment Pharmaceuticals / Net Sales ¥77,950 million / Year-on-year (%) 3.5, Segment Information Services / Net Sales ¥14,237 million / Year-on-year (%) 63, Segment Construction and Facility Maintenance / Net Sales ¥4,331 million / Year-on-year (%) 26.1, Segment Product Sales / Net Sales ¥886 million / Year-on-year (%) 2.9 |
| Segment profit | Segment Pharmaceuticals / Segment profit ¥-4,524 million / Year-on-year (%) Not disclosed, Segment Information Services / Segment profit ¥1,102 million / Year-on-year (%) Not disclosed, Segment Construction and Facility Maintenance / Segment profit ¥595 million / Year-on-year (%) Not disclosed, Segment Product Sales / Segment profit ¥136 million / Year-on-year (%) Not disclosed |
| Depreciation and amortization | ¥4,644 million |
| Impairment loss | No impairment loss recognized for the period (¥0 million) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥833 million, Gain on sale of investment securities ¥17,044 million, Relocation compensation ¥371 million / Extraordinary loss Losses on disposal of fixed assets ¥132 million, Loss on sale of investment securities ¥62 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Newly included: 0 companies; excluded: 0 companies (no material change in the scope of consolidation during the period) |
| Material subsequent events | Entered into an agreement licensing the development and marketing rights for olutasidenib in Taiwan to Orient EuroPharma. Also resolved to acquire up to 1,300,000 shares of treasury stock for a total of up to ¥6 billion and cancel all shares acquired. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 46,541,985 |
| Treasury Shares at Period-End | 5,089,961 |
| Factors Behind Changes in Business Performance | Revenue increased in the Pharmaceuticals business due to growth in sales of major products and in the Information Services business due to orders for projects related to the GIGA School Program. However, higher cost of sales as a percentage of revenue and increased selling, general and administrative expenses, mainly research and development expenses, resulted in an operating loss and an ordinary loss, while gains on sales of investment securities led to an increase in net income. |
Items this document does not state (3)
Revision to Earnings ForecastRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as Beova, Tabuneos, Kolsvad and Tavalisse, among other products, grew in the Pharmaceuticals business, while the Information Services business received orders for projects related to the GIGA School Program. In terms of earnings, higher cost of sales as a percentage of revenue and increased selling, general and administrative expenses, mainly research and development expenses, resulted in an operating loss and an ordinary loss. However, net income attributable to owners of the parent increased due to the recording of gains on sales of investment securities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.